Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates

Luca A Robinson1, Alice C Z Collins1, Ronan A Murphy1

  • 1National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Frontiers in Microbiology
|January 23, 2023
PubMed

Insights

Pseudomonas aeruginosa

Area of Science:

  • Microbiology
  • Genomics
  • Bacterial Pathogenesis

Background:

  • Pseudomonas aeruginosa is a significant cause of illness and death in Cystic Fibrosis (CF) patients.
  • The Type VI secretion system (T6SS) is crucial for bacterial interactions and virulence.
  • Genetic diversity of T6SS effectors in P. aeruginosa clinical isolates remains underexplored.

Purpose of the Study:

  • To comprehensively analyze the pangenome and T6SS effector genes in clinical P. aeruginosa isolates from CF patients.
  • To investigate the genetic diversity and variability of T6SS loci and effectors in these isolates.
  • To identify novel T6SS effectors and assess their prevalence.

Main Methods:

  • Bioinformatic analysis of 52 high-quality clinical P. aeruginosa genomes from CF patients.
  • Pangenome analysis to identify accessory and unique genes.
  • Comparative analysis of T6SS genomic loci and effector genes against reference strains.
  • In silico identification of novel effector genes and islands.
  • Prevalence assessment of T6SS effectors in 532 public P. aeruginosa genomes.

Main Results:

  • The clinical CF isolate pangenome is open, characterized by accessory and unique genes.
  • Significant genetic variability was observed in effector/immunity genes, with absence of some known T6SS islands.
  • Disruptions in T6SS loci due to mobile genetic elements were evident.
  • A novel orphan vgrG island (vgrG7) was identified, potentially encoding a Tle2 lipase effector.
  • Eight new putative T6SS effectors (cytidine deaminase, lipase, metallopeptidase, NADase, pyocin) were identified.
  • Prevalence analysis suggests the existence of accessory T6SS effectors in P. aeruginosa.

Conclusions:

  • Clinical P. aeruginosa isolates, especially from CF patients, exhibit substantial genetic diversity in T6SS genomic loci.
  • This diversity includes novel effectors and variations in known T6SS components, impacting bacterial competition and host interaction.
  • The findings provide a foundation for future experimental studies on T6SS effectors in P. aeruginosa pathogenesis.